GDTC Quote, Financials, Valuation and Earnings

Haw Par has a net margin of -- compared to CytoMed Therapeutics's net margin of --. CytoMed Therapeutics's return on equity of -- beat Haw Par's return on equity of 6.62%.

CytoMed Therapeutics has a consensus price target of --, signalling upside risk potential of 44.93%. On the other hand Haw Par has an analysts' consensus of -- which suggests that it could fall by --. Given that CytoMed Therapeutics has higher upside potential than Haw Par, analysts believe CytoMed Therapeutics is more attractive than Haw Par.

CytoMed Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Haw Par has a beta of 0.120, suggesting its less volatile than the S&P 500 by 88.041%.

CytoMed Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haw Par offers a yield of 3.76% to investors and pays a quarterly dividend of $0.15 per share. CytoMed Therapeutics pays -- of its earnings as a dividend. Haw Par pays out 35.78% of its earnings as a dividend. Haw Par's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytoMed Therapeutics quarterly revenues are --, which are smaller than Haw Par quarterly revenues of --. CytoMed Therapeutics's net income of -- is lower than Haw Par's net income of --. Notably, CytoMed Therapeutics's price-to-earnings ratio is -- while Haw Par's PE ratio is 10.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoMed Therapeutics is -- versus 10.01x for Haw Par. Usually stocks with elevated PS ratios are considered overvalued.

Mobile-health Network Solutions has a net margin of -- compared to CytoMed Therapeutics's net margin of --. CytoMed Therapeutics's return on equity of -- beat Mobile-health Network Solutions's return on equity of -1223.46%.

CytoMed Therapeutics has a consensus price target of --, signalling upside risk potential of 44.93%. On the other hand Mobile-health Network Solutions has an analysts' consensus of -- which suggests that it could grow by 2018.64%. Given that Mobile-health Network Solutions has higher upside potential than CytoMed Therapeutics, analysts believe Mobile-health Network Solutions is more attractive than CytoMed Therapeutics.

CytoMed Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mobile-health Network Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CytoMed Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mobile-health Network Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoMed Therapeutics pays -- of its earnings as a dividend. Mobile-health Network Solutions pays out -- of its earnings as a dividend.

CytoMed Therapeutics quarterly revenues are --, which are smaller than Mobile-health Network Solutions quarterly revenues of --. CytoMed Therapeutics's net income of -- is lower than Mobile-health Network Solutions's net income of --. Notably, CytoMed Therapeutics's price-to-earnings ratio is -- while Mobile-health Network Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoMed Therapeutics is -- versus 0.93x for Mobile-health Network Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Raffles Medical Group has a net margin of -- compared to CytoMed Therapeutics's net margin of --. CytoMed Therapeutics's return on equity of -- beat Raffles Medical Group's return on equity of 5.89%.

CytoMed Therapeutics has a consensus price target of --, signalling upside risk potential of 44.93%. On the other hand Raffles Medical Group has an analysts' consensus of -- which suggests that it could fall by --. Given that CytoMed Therapeutics has higher upside potential than Raffles Medical Group, analysts believe CytoMed Therapeutics is more attractive than Raffles Medical Group.

CytoMed Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Raffles Medical Group has a beta of 0.097, suggesting its less volatile than the S&P 500 by 90.255%.

CytoMed Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Raffles Medical Group offers a yield of 2.66% to investors and pays a quarterly dividend of $0.02 per share. CytoMed Therapeutics pays -- of its earnings as a dividend. Raffles Medical Group pays out 78.41% of its earnings as a dividend. Raffles Medical Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytoMed Therapeutics quarterly revenues are --, which are smaller than Raffles Medical Group quarterly revenues of --. CytoMed Therapeutics's net income of -- is lower than Raffles Medical Group's net income of --. Notably, CytoMed Therapeutics's price-to-earnings ratio is -- while Raffles Medical Group's PE ratio is 27.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoMed Therapeutics is -- versus 2.41x for Raffles Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

WAVE Life Sciences has a net margin of -- compared to CytoMed Therapeutics's net margin of -167.19%. CytoMed Therapeutics's return on equity of -- beat WAVE Life Sciences's return on equity of -437.99%.

CytoMed Therapeutics has a consensus price target of --, signalling upside risk potential of 44.93%. On the other hand WAVE Life Sciences has an analysts' consensus of $22.30 which suggests that it could grow by 65.06%. Given that WAVE Life Sciences has higher upside potential than CytoMed Therapeutics, analysts believe WAVE Life Sciences is more attractive than CytoMed Therapeutics.

CytoMed Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison WAVE Life Sciences has a beta of -1.070, suggesting its less volatile than the S&P 500 by 207.018%.

CytoMed Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WAVE Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoMed Therapeutics pays -- of its earnings as a dividend. WAVE Life Sciences pays out -- of its earnings as a dividend.

CytoMed Therapeutics quarterly revenues are --, which are smaller than WAVE Life Sciences quarterly revenues of -$7.7M. CytoMed Therapeutics's net income of -- is lower than WAVE Life Sciences's net income of -$61.8M. Notably, CytoMed Therapeutics's price-to-earnings ratio is -- while WAVE Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoMed Therapeutics is -- versus 31.64x for WAVE Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.